Loading…
Loading…
EQUITY / NASDAQ · XNCM
Lipocine Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗2.05 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 2.05 USD · Volume 38,944
251 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Revenue | 190,099 USD | — | — |
| Operating profit | -2,842,246 USD | — | — |
| Net income | -2,622,595 USD | — | — |
| Cash and cash equivalents | 4,979,430 USD | — | — |
| Total liabilities | 2,067,957 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 203/31/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 101/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 4,979,430 USD | — | — | 5,015,608 USD | 5,205,842 USD | 5,205,842 USD | 3,901,040 USD | — |
| Net incomeIncome statement | -2,622,595 USD | -6,294,489 USD | — | -3,671,894 USD | — | -9,627,505 USD | -3,186,832 USD | -7,257,421 USD |
| Operating profitIncome statement | -2,842,246 USD | -6,691,711 USD | — | -3,849,464 USD | — | -10,371,379 USD | -3,361,040 USD | -7,855,578 USD |
| RevenueIncome statement | 190,099 USD | 309,496 USD | — | 119,397 USD | — | 1,976,677 USD | 114,574 USD | 831,287 USD |
| Total assetsBalance sheet | 23,835,361 USD | — | — | 25,358,166 USD | 17,005,612 USD | 17,005,612 USD | 16,073,167 USD | — |
| Total equityBalance sheet | 21,767,404 USD | — | 22,830,323 USD | 22,830,323 USD | 14,477,416 USD | 14,477,416 USD | 14,142,048 USD | — |
| Total liabilitiesBalance sheet | 2,067,957 USD | — | — | 2,527,843 USD | 2,528,196 USD | 2,528,196 USD | 1,931,119 USD | — |
| Financing cash flowCash flow statement | — | 13,478,780 USD | — | 11,971,042 USD | — | 2,869,552 USD | — | 216,952 USD |
| Investing cash flowCash flow statement | — | -8,419,628 USD | — | -9,904,139 USD | — | 5,891,085 USD | — | 4,319,376 USD |
| Operating cash flowCash flow statement | — | -5,285,564 USD | — | -2,257,137 USD | — | -9,760,721 USD | — | -6,841,214 USD |
| Report source | Open report ↗ Published: 08/04/2026 | Open report ↗ Published: 08/04/2026 | Open report ↗ Published: 08/04/2026 | Open report ↗ Published: 05/07/2026 | Open report ↗ Published: 08/04/2026 | Open report ↗ Published: 03/10/2026 | Open report ↗ Published: 11/06/2025 | Open report ↗ Published: 11/06/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.